WM_PDX#87_KR_COAD_PX_0002_01_01	PDX #87		C87	Colon	+					WM_PDX#87_KR_COAD_PX_0002_01_01 (4).jpg	Colorectal cancer	P5	HBSS	18.11.02	18.11.20	Day18	Day 28 - Vehicle 평균 2825 mm3	WM-S1-030 – 50 mg/kg에서 단독 효능 평가	WM-S1-030 50 mg/kg : 83.1%	이민기;이미소
WM_PDX#87_KR_COAD_PX_0002_01_02	PDX #87		C87	Colon	+					WM_PDX#87_KR_COAD_PX_0002_01_02 (3).jpg	Colorectal cancer	P5	HBSS	18.12.18	19.01.04	Day17	Day 28 - Vehicle 평균 1777 mm3	WM-S1-030, BMS-777607, Cetuximab 단독, 병용 효능 평가	BMS-777607 30 mg/kg : 18.5%;WM-S1-030 30 mg/kg : 73.1%;Cetuximab 40 mg/kg : 91.9 %;BMS+Cetux : 86.4 %;WM-S1 + Cetux : 94.7 %	이민기;이미소
WM_PDX#116_KR_COAD_PX_0003_01_01	PDX #116		C116	Colon	+					WM_PDX#116_KR_COAD_PX_0003_01_01 (3).jpg	Colorectal cancer	P5	HBSS	19.02.22	19.03.11	Day17	Day 28 - Vehicle 평균 715 mm3	WM-S1-030 – 50 mg/kg에서 단독 효능 평가	WM-S1-030 50 mg/kg : 39.4%	이민기;이준형
WM_PDX#116_KR_COAD_PX_0003_01_02	PDX #116		C116	Colon	+					WM_PDX#116_KR_COAD_PX_0003_01_02 (3).jpg	Colorectal cancer	P5	HBSS	19.03.06	19.03.22	Day16	Day 28 - Vehicle 평균 1473 mm3	WM-S1-030, BMS-777607, Cetuximab 단독, 병용 효능 평가	BMS-777607 50 mg/kg : 31.1 %;WM-S1-030 50 mg/kg : 56.8 %;Cetuximab 40 mg/kg : 16.3 %;BMS+Cetux : 31.8 %;WM-S1 + Cetux : 74.2 %	이민기;이준형
WM_PDX#87_KR_COAD_PX_0002_01_03	PDX #87		C87	Colon	+					WM_PDX#87_KR_COAD_PX_0002_01_03 (3).jpg	Colorectal cancer	P5	HBSS	19.05.02	19.05.16	Day14	Day 28 - Vehicle 평균 2029 mm3	WM-S1-030, BMS-777607, Crizotinib - 10, 30 mg/kg에서 단독 효능 평가	BMS-777607 10 mg/kg : 31.3 %;BMS-777607 30 mg/kg : 50.4 %;Crizotinib 10 mg/kg : 25.8 %;Crizotinib 10 mg/kg : 25.6 %;WM-S1-030 10 mg/kg : 79.5 %;WM-S1-030 10 mg/kg : 86.5 %	이민기;이준형